Looking at the Big Picture for Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc. (NASDAQ:CLRB) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 26.42M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For CLRB, the company currently has 8.37 million of cash on the books, which is offset by 2,877 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 12.6 million in total assets, balanced by 1.74 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Cellectar Biosciences, Inc. (CLRB) saw -2.92 million in free cash flow last quarter, representing a quarterly net change in cash of -2.93 million. Perhaps most importantly where cash movements are concerned, the company saw about -2.66 million in net operating cash flow.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the CLRB saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Cellectar Biosciences, Inc. (CLRB) is intriguing when broken down to its core data. The cost of selling goods last quarter was 101,414, yielding a gross basic income of -101,414 . For shareholders, given the total diluted outstanding shares of 13.46 million, this means overall earnings per share of -0.23.

Is Cellectar Biosciences, Inc. (NASDAQ:CLRB) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.92 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Cellectar Biosciences, Inc..

Previous ArticleNext Article

Related Post

Comparing Snap Inc. (SNAP) and Square, Inc. (SQ) Snap Inc. (NYSE:SNAP) shares are down more than -48.65% this year and recently increased 1.37% or $0.17 to settle at $12.57. Square, Inc. (NYSE:SQ), o...
Taking a Look at the Operational Data for Dycom In... Dycom Industries, Inc. (NYSE:DY) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 2.48B...
Comparing Snap Inc. (SNAP) and Square, Inc. (SQ) Snap Inc. (NYSE:SNAP) shares are up more than 0.27% this year and recently increased 3.90% or $0.55 to settle at $14.65. Square, Inc. (NYSE:SQ), on th...
It’s worth it to have a look at Caesars Ente... It is interesting to note that Caesars Entertainment Corporation (NASDAQ:CZR) is active and made a solid movement in the last trading day. Now trading...
Advaxis, Inc. (ADXS) vs. Jaguar Health, Inc. (JAGX... Advaxis, Inc. (NASDAQ:ADXS) shares are down more than -47.07% this year and recently decreased -3.56% or -$0.14 to settle at $3.79. Jaguar Health, Inc...